• Most Popular
  • Most Shared

U.S. FDA to review data on Vytorin cancer risk

Thu Aug 21, 2008 3:32pm EDT

Stocks

   

WASHINGTON, Aug 21 (Reuters) - U.S. Food and Drug Administration officials plan to review recently publicized data that showed a higher rate of cancer in patients taking Merck & Co Inc (MRK.N) and Schering-Plough Corp's SGP.N cholesterol drug Vytorin.

Stocks  |  Regulatory News

The agency, in a notice posted on its website on Thursday, said it will take about three months before it receives final results from the so-called SEAS study. It will likely take another six months for the FDA to complete its review and draw any conclusions, it added. (Reporting by Susan Heavey; Editing by Tim Dobbyn)

Stocks
Regulatory News


More from Reuters

Photo

Fox, Time Warner Cable ink temp deal to avoid blackout

NEW YORK (Reuters) - Time Warner Cable and News Corp's Fox Networks agreed to a brief extension of their current carriage contract on Thursday to avoid a blackout that would have prevented 13 million U.S. homes from seeing TV shows like "The Simpsons" and college and NFL football games.

» More Top News
A customer is served at a counter inside a foreign exchange store displaying a poster of various banknotes including the Chinese yuan or renminbi (RMB) in Hong Kong November 20, 2009. REUTERS/Bobby Yip
OUTLOOK 2010:

Be careful what you wish for

Pressure on China to loosen its grip on the yuan will continue but the U.S. should tread carefully. Here are five world market issues to watch.  Full Article 

Global Markets
Clients work out on machines at the Bally Total Fitness facility in Arvada, Colorado June 15, 2009. REUTERS/Rick Wilking

Get real with resolutions

We make them and we break them: The secret to keeping them is to avoid the impossible dream.  Full Article 

Lifestyle